Showing 5501-5510 of 7091 results for "".
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c
- Candela Launches the All-New Profound Matrix Systemhttps://practicaldermatology.com/news/candela-launches-the-all-new-profound-matrix-system/2461544/Candela is rolling out the all-new Profound Matrix system. This multi-application system features the Sublime, Sublative radiofrequency (RF), and all-new Matrix Pro applicators. The Sublime and Sublative RF applicators deliver bipolar RF treatments that improve the appearance of fine li
- Avero Diagnostics Launches Test for Early-Stage Melanoma Progressionhttps://practicaldermatology.com/news/avero-diagnostics-launches-test-for-early-stage-melanoma-progression/2461541/Avero Diagnostics announced the US launch of AMBLor, a laboratory test for the identification of early-stage melanomas at low risk of progression. AMBLor technology identifies the presence of two prognostic biomarker proteins, AMBRA1 and loricrin, in the skin overlying the tumor, a
- CDC Report: Seven Percent of Adults and 11 Percent of Kids Had Eczema in 2021https://practicaldermatology.com/news/cdc-report-seven-percent-of-adults-and-11-percent-of-kids-had-eczema-in-2021/2461530/Slightly more than 7% of adults and nearly 11% of kids had eczema in 2021, according to two new reports in the CDC’s National Center for Health Statistics Data Brief. W
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Study: 3D-printed Artificial Skin Can Be Used in Cosmetics and Drug Testinghttps://practicaldermatology.com/news/study-3d-printed-artificial-skin-can-be-used-in-cosmetics-and-drug-testing/2461525/Bioprinted artificial skin can be used in cosmetics and drug testing, a new study shows. For the study, researchers compared the conventional mimetic model based on manual pipetting with extrusion bioprinting, which “allows the in vitro reconstruction of a more relevant and repres
- Mount Sinai Researchers Awarded $12 Million NIH Grant to Create a Center to Study Causes of Atopic Dermatitis and Food Allergyhttps://practicaldermatology.com/news/mount-sinai-researchers-awarded-12-million-nih-grant-to-create-a-center-to-study-causes-of-atopic-dermatitis-and-food-allergy/2461520/Mount Sinai researchers have been awarded $12 million over 5 years by the National Institutes of Health (NIH) to create a center to elucidate novel causes of, and contributing factors to, food allergies and atopic dermatitis, according to a news release. The Systems Biology of Early Ato
- Amazon Launches $5-a-Month Subscription Service for Generic Drugshttps://practicaldermatology.com/news/amazon-launches-5-a-month-subscription-service-for-generic-drugs-1/2461518/In its latest move into the healthcare and pharmacy business, Amazon announced the launch of RxPass, a new benefit for Prime members that offers patients access to commonly prescribed generic medications that treat more than 80 heal
- Update: Two More Payers to Cover DermTech’s Melanoma Testhttps://practicaldermatology.com/news/update-two-more-payers-to-cover-dermtechs-melanoma-test/2461514/Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people. The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. T
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T